Therapy Detail

Therapy Name Prexasertib
Synonym
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Prexasertib LY2606368|IC-83 CHK1 Inhibitor 14 Prexasertib (LY2606368) inhibits checkpoint kinase 1 (Chk1), which may result in accumulation of DNA damage and decreased tumor growth (PMID: 26141948, PMID: 28270495).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Prexasertib Phase I Actionable In a Phase I trial, Prexasertib (LY2606368) treatment resulted in partial response in 4.4% (2/45) and stable disease ranging from 1.2 to 6.7 months in 33.3% (15/45) of patients with advanced solid tumors (PMID: 27044938). 27044938
Unknown unknown squamous cell carcinoma not applicable Prexasertib Phase Ib/II Actionable In a Phase Ib trial, Prexasertib (LY2606368) demonstrated safety and resulted in a clinical benefit rate at 3 months of 29% (29/101) in squamous cell carcinoma patients, including patients with squamous cell carcinoma of the anus, head and neck squamous cell carcinoma, and squamous non-small cell lung cancer (PMID: 29643063; NCT0115790). 29643063
Unknown unknown squamous cell carcinoma not applicable Prexasertib Phase I Actionable In a Phase I trial, Prexasertib (LY2606368) treatment resulted in partial response in 2 patients with squamous cell carcinoma (SCC), and 40% (6/15) of solid tumor patients who achieved stable disease had SCC (PMID: 27044938; NCT0115790). 27044938
Unknown unknown Ewing sarcoma not applicable Prexasertib Preclinical - Cell culture Actionable In a preclinical study, Prexasertib (LY2606368) decreased proliferation of several pediatric tumor cell lines in culture, including Ewing sarcoma cell lines (PMID: 28270495). 28270495
Unknown unknown rhabdomyosarcoma not applicable Prexasertib Preclinical - Cell culture Actionable In a preclinical study, Prexasertib (LY2606368) decreased proliferation of several pediatric tumor cell lines in culture, including rhabdomyosarcoma cell lines (PMID: 28270495). 28270495
BRCA1 wild-type BRCA2 wild-type ovarian serous carcinoma predicted - sensitive Prexasertib Phase II Actionable In a Phase II trial, Prexasertib (LY2606368) treatment resulted in a partial response in 33% (8/24) of BRCA wild-type patients with high-grade serous ovarian cancer (PMID: 29361470; NCT02203513). 29361470
Unknown unknown head and neck squamous cell carcinoma not applicable Prexasertib Preclinical - Cell culture Actionable In a preclinical study, head and neck squamous cell carcinoma cell lines, either human papilloma virus positive or negative, demonstrated decreased cell proliferation in culture when treated with Prexasertib (LY2606368) (PMID: 28138028). 28138028
Unknown unknown head and neck squamous cell carcinoma not applicable Prexasertib Phase Ib/II Actionable In a Phase Ib trial, treatment with Prexasertib (LY2606368) resulted in an overall response rate of 5% (3/57, all partial responses), clinical benefit rate (complete response+partial response+stable disease) of 49% (28/57), and a median progression-free survival of 1.6 months in patients with head and neck squamous cell carcinoma (PMID: 29643063; NCT0115790). 29643063
Unknown unknown head and neck squamous cell carcinoma not applicable Prexasertib Phase I Actionable In a Phase I trial, Prexasertib (LY2606368) treatment resulted in partial response in a patient with head and neck squamous cell carcinoma (PMID: 27044938; NCT0115790). 27044938
Unknown unknown osteosarcoma not applicable Prexasertib Preclinical - Cell culture Actionable In a preclinical study, Prexasertib (LY2606368) decreased proliferation of several pediatric tumor cell lines in culture, including osteosarcoma cell lines (PMID: 28270495). 28270495
Unknown unknown medulloblastoma not applicable Prexasertib Preclinical - Cell culture Actionable In a preclinical study, Prexasertib (LY2606368) decreased proliferation of several pediatric tumor cell lines in culture, including medulloblastoma cell lines (PMID: 28270495). 28270495
Unknown unknown neuroblastoma not applicable Prexasertib Preclinical - Cell line xenograft Actionable In a preclinical study, Prexasertib (LY2606368) decreased proliferation and increased apoptosis of neuroblastoma cell lines in culture, and induced tumor regression in neuroblastoma cell line xenograft models (PMID: 28270495). 28270495
Unknown unknown retinoblastoma not applicable Prexasertib Preclinical - Cell culture Actionable In a preclinical study, Prexasertib (LY2606368) decreased proliferation of several pediatric tumor cell lines in culture, including a retinoblastoma cell line (PMID: 28270495). 28270495
Unknown unknown anal squamous cell carcinoma not applicable Prexasertib Phase I Actionable In a Phase I trial, Prexasertib (LY2606368) treatment resulted in partial response in a patient with anal squamous cell carcinoma (PMID: 27044938). 27044938
Unknown unknown anal squamous cell carcinoma not applicable Prexasertib Phase Ib/II Actionable In a Phase Ib trial, treatment with Prexasertib (LY2606368) resulted in an overall response rate of 15% (4/26; 1 complete response (CR) and 3 partial responses (PR)), a clinical benefit rate (CR+PR+stable disease) of 58% (15/26), and a median progression-free survival of 2.8 months in patients with squamous cell carcinoma of the anus (PMID: 29643063; NCT0115790). 29643063
Unknown unknown acute lymphocytic leukemia not applicable Prexasertib Preclinical - Cell culture Actionable In a preclinical study, Prexasertib (LY2606368) decreased proliferation of several pediatric tumor cell lines in culture, including acute lymphoblastic leukemia cell lines (PMID: 28270495). 28270495
Unknown unknown lung squamous cell carcinoma not applicable Prexasertib Phase Ib/II Actionable In a Phase Ib trial, treatment with Prexasertib (LY2606368) resulted in a clinical benefit rate (complete response+partial response+stable disease) of 56% (9/16, all stable disease), and a median progression-free survival of 3.0 months in patients with squamous non-small cell lung cancer (PMID: 29643063; NCT0115790). 29643063
Clinical Trial Phase Therapies Title Recruitment Status
NCT02555644 Phase I Prexasertib Cisplatin Cetuximab A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer Completed
NCT03414047 Phase II Prexasertib A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer Active, not recruiting
NCT02735980 Phase II Prexasertib A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer Completed
NCT02808650 Phase I Prexasertib Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Recruiting
NCT02873975 Phase II Prexasertib A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency Recruiting
NCT02203513 Phase II Prexasertib A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer Recruiting